ReviewJournal of nephrology2015
Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab.
Review in Journal of nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Isolated Sensorineural Hearing Loss as the Sole Manifestation of Granulomatosis with Polyangiitis.The American journal of case reports · 2025Article
- Sequelae of B-Cell Depleting Therapy: An Immunologist's Perspective.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- A 79-Year-Old Woman With Worsening Headaches and Pachymeningeal Enhancement: A Case Report From the National Multiple Sclerosis Society Case Conference Proceedings.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Management of Coronary Artery Diseases in Systemic Vasculitides: Complications and Strategies.Medicina (Kaunas, Lithuania) · 2024Review
- Subglottic Stenosis as a Presentation of Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis.Cureus · 2023Article
- Review
- Isolated deafness as a presenting symptom in granulomatosis with polyangiitis.BMJ case reports · 2021Article
- An Interesting Case of Bilateral Facial Palsy due to Granulomatosis with Polyangiitis.Case reports in rheumatology · 2021Article
- Effects of rituximab therapy on B cell differentiation and depletion.Clinical rheumatology · 2020Review
- Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?ImmunoTargets and therapy · 2020Review
- Granulomatosis with polyangiitis: potentially lethal gingival lesions presenting to the dentist.BMJ case reports · 2019Article
- Article
- Rituximab for treatment of severe renal disease in ANCA associated vasculitis.Journal of nephrology · 2016Article
- Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.ImmunoTargets and therapy · 2015Review
- The pharmacological treatment of granulomatosis with polyangiitis: a review of clinical trials registered in clinicaltrials.gov and the International Clinical Trials Registry Platform.Therapeutic advances in rare diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Granulomatosis with polyangiitis and microscopic polyangiitis are anti-neutrophil cytoplasmic antibody-associated vasculitides (AAVs) that are prone to cycles of remission and relapse. The introduction of cytotoxic therapy has changed the prognosis for these diseases from typically fatal to manageable chronic illnesses with a relapsing course. Despite improvements in outcomes, recurrence of disease and drug-related toxicity continue to produce significant morbidity and mortality. Better understanding of the pathogenesis of AAV and the mechanism of action of cyclophosphamide has led to investigation of therapies that target B cells. Two randomized controlled trials have shown that rituximab is not inferior to cyclophosphamide for induction of remission in severe AAV, with no significant difference in the incidence of overall adverse events in rituximab- versus cyclophosphamide-treated patients. Data from ongoing clinical trials will determine the role of rituximab in the maintenance of remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.